Varennes, Quebec, April 19, 2024 /CNW/ – Canadian pharmaceutical company Nora Pharma has received approval for its first biosimilar product.
Nora Pharma, a wholly owned division of Sunshine Biopharma, has received approval from Health Canada to commercialize NIOPEG®, a pegylated form of filgrastim. Canada.
“With this product, we demonstrate to the Canadian market our commitment to becoming a leader in the pharmaceutical sector.” Malek Chamon, President of Nora Pharma. “This is an important milestone in our mission to bring high-quality, affordable medicines to patients around the world.” Canada,” he added.
NIOPEG® is a biosimilar comparable to the reference biologic NEULASTA® (pegfilgrastim). NIOPEG® is a long-acting recombinant human granulocyte colony-stimulating factor (r-HuG-CSF), or filgrastim. It has been shown to reduce the incidence of infections manifesting as febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic agents. NIOPEG® is available in 6 mg/0.6 mL prefilled syringes.
“NIOPEG® is used to prevent infection in non-myeloid cancer patients undergoing chemotherapy. An example of non-myeloid cancer is breast cancer,” he said. steve slilati, CEO of Sunshine Biopharma. “Biosimilars will have a significant impact on the sustainability of pharmaceutical insurance plans and ensure that patients have access to these high-quality treatments for years to come,” he said. continued.
About Nora Pharma Co., Ltd.
Nora Pharma is a Canadian pharmaceutical company that provides generic and specialty medicines nationwide. Nora Pharma is positioned as the partner of choice to optimize service delivery to our pharmacy partners and provide patients with access to quality medicines at affordable prices. For more information, please visit www.norapharma.ca/en/.
About Sunshine Biopharma Co., Ltd.
Sunshine BioPharma, through its subsidiary Nora Pharma, sells 52 generic prescription drugs in the United States. Canada. The company plans to expand its product offering to a total of 60 generic prescription drugs by the end of 2024. In parallel, Sunshine Biopharma is developing (i) K1.1 mRNA for liver cancer and (ii) PLpro protease inhibitor against SARS coronavirus infection. For more information, please visit www.sunshinebiopharma.com.
Source Nora Pharma
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2024/19/c9180.html
